HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Rassnick, K. M. Articles by Njaa, B. L. Search for Related Content PubMed PubMed Citation Articles by Rassnick, K. M. Articles by Njaa, B. L.

Cyclooxygenase-2 immunoreactivity in equine ocular squamous-cell carcinoma

Correspondence: ¹Corresponding Author: Kenneth M. Rassnick, Department of Clinical Sciences, Box no. 31, Cornell University College of Veterinary Medicine Ithaca, New York 14853. kmr32{at}cornell.edu

Squamous-cell carcinoma (SCC) is the second most common tumor in horses, and 40%–50% may occur in ocular and adnexal structures. Cyclooxygenase (COX)-2 is an inducible enzyme responsible for the production of prostaglandins that control cell growth and the development and progression of cancer. Mechanisms responsible for the initial upregulation of COX-2 in neoplasia are unclear; prolonged sunlight exposure and mutations in the p53 gene may be possibilities. Because the etiopathogenesis of ocular SCC in horses may involve ultraviolet sunlight and p53 mutations, the purpose of this study was to characterize the immunoreactivity of COX-2 in these tumors. Cyclooxygenase-2 expression was found in 6 of 22 (27%) paraffin-embedded equine SCCs. Cyclooxygenase-2 immunoreactivity was associated with the mitotic index (P < 0.001). Strategies to inhibit COX-2 by the use of topical or systemic COX-2 inhibitors might prove to be a safe and economical treatment in some horses with SCC.

Key Words: Cancer • eye • horses • immunohistochemistry • neoplasia, ophthalmology